aav2/8.tbg.harsb
Gene therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03173521)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- N-acetylgalactosamine-4-sulfataseSupplementation
ARSB supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aav2/8.tbg.harsb
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03173521 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2017 | Fondazione Telethon |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fondazione Telethon | Academic/Hospital | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1